iQure Pharma and University of Padova Unite for Groundbreaking CNS Research iQure Pharma partners with the University of Padova to advance its CNS disorder research, focusing on restoring glutamate balance for innovative treatments.

iQure Pharma and University of Padova Unite for Groundbreaking CNS Research #United_States #Princeton,_NJ #CNS_disorders #iQure_Pharma #University_of_Padova

iQure Pharma Achieves US Patent for Innovative CNS Drug iQ-007 iQure Pharma has secured a US patent for iQ-007, a groundbreaking drug designed to restore glutamate balance for CNS disorders, aiming to revolutionize treatment for epilepsy.

iQure Pharma Achieves US Patent for Innovative CNS Drug iQ-007 #United_States #Princeton #CNS_disorders #iQure_Pharma #iQ-007

iQure Pharma Welcomes Prof. Iris Loew-Friedrich as New Clinical and R&D Advisor iQure Pharma announces the appointment of Prof. Iris Loew-Friedrich as Clinical and R&D Advisor, enhancing its expertise in CNS disorder treatment research.

iQure Pharma Welcomes Prof. Iris Loew-Friedrich as New Clinical and R&D Advisor #USA #Princeton #CNS_disorders #iQure_Pharma #Iris_Loew-Friedrich